The expression of epidermal growth factor receptor, vascular endothelial growth factor, matrix metalloproteinase-2, and cyclooxygenase-2 in relation to human papilloma viral load and persistence of human papillomavirus after conization with negative margins

International Journal of Gynecological Cancer

Volumn 16, Issue 6, 2006, Pages 2009-2017

  Song, S H ^a   Lee, J K ^a   Hur, J Y ^a   Kim, I ^a   Saw, H S ^a   Park, Y K ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Conization; Cyclooxygenase 2 (COX 2); Epidermal growth factor receptor (EGFR); Matrix metalloproteinase 2 (MMP 2); Vascular endothelial growth factor (VEGF)

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; VASCULOTROPIN; VIRUS DNA;

ARTICLE; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE SECTION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

ADULT; ALPHAPAPILLOMAVIRUS; BIOLOGICAL MARKERS; CONIZATION; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MEMBRANE PROTEINS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRAL LOAD;

EID: 33845533977     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00727.x     Document Type: Article

References (40)

1. Kjaer SK, van den Brule AJ, Paull G et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572-8.
2. Zur Hausen H. Papillomaviruses causing cancer: evasion from host cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-8.
3. Josefsson AM, Magnusson PK, Ylitalo N et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2189-93.
4. Sellors JW, Mahony JB, Kaczorowski J et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 2000;163:503-8.
5. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
6. Chao A, Lin CT, Hsueh S et al. Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization. Am J Obstet Gynecol 2004;190:1046-51.
7. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001;358:1782-3.
8. Chua KL, Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol 1997;66:108-13.
9. Costa S, De Simone P, Venturoli S et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol 2003;90:358-65.
10. Bodner K, Bodner-Adler B, Wierrani F, Kimberger O, Denk C, Grunberger W. Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis. Anticancer Res 2002;22:3733-6.
11. Dalstein V, Riethemuller D, Pretet JL et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396-403.
12. Song SH, Lee JK, Oh MJ et al. Persistent HPV infection after conization in patients with negative margins. Gynecol Oncol 2006;101:418-22.
13. Kim MH, Seo SS, Song YS et al. Expression of cyclooxygenase-1 and-2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes. Gynecol Oncol 2003;90:83-90.
14. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000;19:4611-20.
15. Almadori G, Cadoni G, Cattani P et al. Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma. Clin Cancer Res 2001;7:3988-93.
16. Malina R, Motoyama S, Hamana S, Maruo T. Laminin-5 gamma2 chain and matrix metalloproteinase-2 expression in the neoplastic changes of uterine cervical squamous epithelium. Kobe J Med Sci 2004;50:123-30.
17. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
18. Bequet-Romero M, Lopez-Ocejo O. Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem Biophys Res Commun 2000;277:55-61.
19. Le Buanec H, D'Anna R, Lachgar A et al. HPV-16 E7 but not E6 oncoprotein triggers both cellular immunosuppression and angiogenic processes. Biomed Pharmacother 1999;53:424-31.
20. Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E, Spandidos DA. VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett 2005;221:105-18.
21. Dobbs SP, Hewett PW, Johnson IR, Carmichael J, Murray JC. Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br J Cancer 1997;76:1410-5.
22. Cheng WF, Chen CA, Lee CN, Chen TM, Hsieh FJ, Hsieh CY. Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 1999;93:761-5.
23. Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000;83:620-5.
24. Gaffney DK, Haslam D, Tsodikov A et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:922-8.
25. Tjalma W, Weyler J, Weyn B et al. The association between vascular endothelial growth factor, microvessel density and clincopathological features in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2000;92:251-7.
26. Pim D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992;7:27-32.
27. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993;67:4521-32.
28. Mathur SP, Mathur RS, Rust PF, Young RC. Human papilloma virus (HPV)-E6/E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN). Am J Reprod Immunol 2001;46:280-7.
29. Chapman WB, Lorincz AT, Willett GD, Wright VC, Kurman RJ. Epidermal growth factor receptor expression and the presence of human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynecol Pathol 1992;11:221-6.
30. Pfeiffer D, Stellwag B, Pfeiffer A, Borlinghaus P, Meier W, Scheidel P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1989;33:146-50.
31. Scambia G, Ferrandina G, Distefano M, D'Agostino G, Benedetti-Panici P, Mancuso S. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett 1998;123:135-9.
32. Munkarah A, Ali-Fehmi R. COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol 2005;17:49-53.
33. Banerjee AG, Gopalakrishman VK, Bhattacharya I, Vishwanatha JK. Deregulated cyclooxygenase-2 expression in oral premalignant issues. Mol Cancer Ther 2002;1:1265-71.
34. Kim JY, Lim SJ, Park K, Lee CM, Kim J. Cyclooxygenase-2 and cerbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol 2005;97:37-41.
35. Rye HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000;76:320-5.
36. Chen YJ, Wang LS, Wang PH, Lai CR, Yen MS, Ng HT. High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol Oncol 2003;88:379-85.
37. Landen CN Jr, Mathur SP, Richardson MS, Creasman WT. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol 2003;188:1174-6.
38. Farley J, Uyehara C, Hashiro G, Belnap C, Birrer M, Salminen E. Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecol Oncol 2004;92:596-602.
39. Gaiotto MA, Focchi J, Ribalta JL et al. Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. Am J Obstet Gynecol 2004;190:1278-82.
40. Talvensaari A, Apaja-Sarkkinen M, Hoyhtya M, Westerlund A, Puistola U, Turpeenniemi T. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol Oncol 1999;72:306-11.